P102. Validation of a Portuguese version of the Inflammatory Bowel Disease Disability Score
J. Magalhães, F. Dias de Castro, P. Boal Carvalho, S. Leite, M.J. Moreira, J. Cotter, Centro Hospitalar do Alto Ave, Gastroenterology, Guimaraes, Portugal
Inflammatory bowel disease (IBD) has a physical, psychological and social impact, sometimes compromising patient's ability to perform day-to-day activities. Recently a new measurement for disability in IBD was developed. The IBD-disability score (IBD-DS) comprises the following domains: demographics, mobility, gastrointestinal-related problems, selfcare, major life activities, mental health and interaction with the environment. The aim of our study was to translate to Portuguese and establish the validity of the IBD-DS.
Prospectively, Portuguese patients with Crohn's disease (CD) and ulcerative colitis (UC) completed a Portuguese version of the IBD-DS, the short inflammatory bowel disease questionnaire (SIBDQ). Harvey–Bradshaw (HB) for CD and partial Mayo score (pMayo) for UC were also filled. Statistical analysis was performed with SPSS (version 18.0) and the statistical level of significance was established at 5%. Pearson's correlation coefficient was used to assess the correlation between the IBD-DS and SIBDQ, HB and pMayo scores. The student t-test was used to compare the mean of IBD-DS between active and inactive disease.
A total of 85 IBD outpatients (55 CD and 30 UC) were enrolled. There was a significant negative correlation between the IBD-DS and the SIBDQ (r = −0.858 and r = −0.933 for CD and UC, respectively). The HB for CD and the pMayo for UC presented a moderate positive correlation with the IBD-DS (r = 0.460 and r = 0.585, respectively). The IBD-DS accurately distinguished between inactive vs. active disease (93.78 vs. 117.57, p = 0.016 for CD and 78.96 vs. 137.14, p < 0.001 for UC).
Our Portuguese version of the inflammatory bowel disease disability score correlates well with the patients' quality of life and clinical disease activity and seems a valid tool to measure disability in patients with inflammatory bowel disease.